Bruce Sachais, MD, PhD
Vice President, Enterprise Chief Medical Officer
Head, Laboratory of Platelet Research
Associate Member, Lindsley F. Kimball Research Institute
The Platelet Research Laboratory is interested in the pathobiology of platelets and platelet molecules. We are currently focused on improved diagnosis and novel therapeutics for heparin induced thrombocytopenia/thrombosis (HITT). We have recently published on novel assays which may improve the precision and accuracy for diagnosis HITT. Have also published on novel small molecules that interfere with the formation of heparin:PF4 complexes, which we call PF4 Antagonists (POF4As). We are actively working to improve the potency and pharmacology of PF4As towards the development of PF4As as a therapeutic option for the treatment and/or prevention of HIT. We are also interested in the pathgobiology of HIT as well as other platelet disorders.
NIH R42 HL123126 PI: Sachais 09/2016 - 07/2019 (NCE) "Small Molecule Antagonists of PF4 for the treatment and prevention of HIT, Phase II"
NIH R44HL145783 Tabadadze (PI); Sachais (NYBC PI) 03/2019-02/2022 " A closed system for pathogen reduction of red blood cells for transfusion”
75N92019D00037 Hod (PI); Sachais (NYBC PI) 04/2019-03/2026 Recipient Epidemiology and Donor Evaluation Study IV-P Domestic Hub (Federal Gov)
Education and Training
M.D. Washington University
Ph.D. Washington University (Neuroscience)
Pathology and Laboratory Medicine, University of Pennsylvania, School of Medicine
Certificate in Patient Oriented Research, University of Pennsylvania